ERBB2 and neoplasm: Its ability to inhibit in vitro and in vivo tumor growth [21] is attributed to internalization and down-regulation of cell surface HER2 [22], inhibition of the PI3K/Akt pathway [23], cell cycle arrest in G1, inhibition of angiogenesis [24], and antibody-dependent cell-meditated cytotoxicity (ADCC) [25,26,27].